Immunic (IMUX)
(Delayed Data from NSDQ)
$1.45 USD
+0.06 (4.32%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $1.43 -0.02 (-1.38%) 5:44 PM ET
3-Hold of 5 3
F Value B Growth C Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
IMUX 1.45 +0.06(4.32%)
Will IMUX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for IMUX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IMUX
Immunic's (IMUX) Ulcerative Colitis Study Shows Positive Data
Immunic (IMUX) Moves to Buy: Rationale Behind the Upgrade
IMUX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Immunic (IMUX) Falls as Phase II Ulcerative Colitis Study Fails
Other News for IMUX
Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Experienced Pharmaceutical Executive Simona Skerjanec
Immunic Stock (NASDAQ:IMUX): Exploring the Promising Phase 2 CALLIPER Trial
Immunic to present four abstracts at ECTRIMS, says Piper Sandler
Immunic Appoints Jason Tardio as Chief Operating Officer and President
Immunic Stock (IMUX): Deep Dive into Lead Candidate, Vidofludimus Calcium